Novo Acquires Three Kallyope Obesity Programs

Company Novo Nordisk / Kallyope Event Type Asset Acquisition Modality Peptide and Small-Molecule Non-Incretin Obesity Therapies Asset K-554 (IND-Ready Peptide), Plus a Follow-On Small Molecule and a Separate Receptor Agonist Target Undisclosed Non-Incretin Targets Disease Area Obesity Summary Novo Nordisk acquired three early-stage non-incretin obesity…